In the meanwhile, our research provided correlation analyses between FGF2-FGFR1 and downstream pathways, utilizing patient databases, and underscored the potential adverse consequences associated with the monotherapy of FGFR inhibitors in clinical treatments for ER + breast cancer. This evidence concerns the gene FGF2 and breast carcinoma.